13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q4 2019. See the latest, Q2 2026 →
Reported value
$1.65B
−50% on the quarter before
Positions
24
2 new · 2 sold out
Top 10
93.2%
of the value
Est. gain
+$187.5M
on stocks held all quarter
Est. return
+14.8%
on those stocks since Q3 2019
Positions as of Dec 31, 2019, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2019. Striped tiles are options.
Largest buys
Since Q3 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Dexcom Inc~$152.1MAdded · 0.5% → 10.7%+695,224 shares
- Rapt Therapeutics Inc~$23.1MNew · 0.0% → 1.4%+836,059 shares
- Vir Biotechnology Inc~$21.0MNew · 0.0% → 1.3%+1,666,666 shares
- CrowdStrike~$1.5MAdded · 0.2% → 0.5%+31,020 shares
Largest sells
Since Q3 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Uber~$2.00BCut · 65.1% → 6.8%−67,357,104 shares
- Forty Seven Inc~$20.3MCut · 0.3% → 2.5%−515,322 shares
- Cortexyme Inc~$6.9MCut · 0.2% → 0.6%−122,980 shares
- Block~$765,000Sold out · 0.0% → 0.0%−12,342 shares
- Alector Inc~$372,302Cut · 0.1% → 0.2%−21,609 shares
- S&P Global Inc~$318,000Sold out · 0.0% → 0.0%−1,297 shares
Holdings
As of Dec 31, 2019. Changes are in shares against Sep 30, 2019, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lyft IncCL A COM · shares 0% · price +5.3% | 33.4% | $551.9M | +$28.0M | ||||||||
| Jd Com IncSPON ADR CL A · shares 0% · price +24.9% | 28.9% | $477.5M | +$95.1M | ||||||||
| Dexcom IncCOM · shares +629% · price +46.6% | 10.7% | $176.2M | +$7.7M | ||||||||
| UberCOM · shares −95% · price −2.4% | 6.8% | $112.5M | −$2.8M | ||||||||
| Arcus Biosciences IncCOM · shares 0% · price +11.0% | 3.1% | $51.0M | +$5.0M | ||||||||
| Magenta Therapeutics IncCOM · shares 0% · price +47.8% | 3.1% | $50.6M | +$16.4M | ||||||||
| Forty Seven IncCOM · shares −33% · price +513.2% | 2.5% | $40.6M | +$34.0M | ||||||||
| Slack Technologies Inc.COM CL A · shares 0% · price −5.3% | 1.8% | $29.2M | −$1.6M | ||||||||
| CloudflareCL A COM · shares 0% · price −8.1% | 1.7% | $27.9M | −$2.5M | ||||||||
| Rapt Therapeutics IncCOM · shares New | 1.4% | $23.1M | — | ||||||||
| Vir Biotechnology IncCOM · shares New | 1.3% | $21.0M | — | ||||||||
| Fulcrum Therapeutics IncCOM · shares 0% · price +150.6% | 0.72% | $11.9M | +$7.1M | ||||||||
| Spero Therapeutics IncCOM · shares 0% · price −9.3% | 0.65% | $10.7M | −$1.1M | ||||||||
| Cortexyme IncCOM · shares −39% · price +125.2% | 0.64% | $10.6M | +$5.9M | ||||||||
| Autolus Therapeutics PlcSPON ADS · shares 0% · price +6.3% | 0.56% | $9.2M | +$545,000 | ||||||||
| SnapCL A · shares 0% · price +3.3% | 0.52% | $8.6M | +$277,000 | ||||||||
| CrowdStrikeCL A · shares +22% · price −14.5% | 0.52% | $8.5M | −$1.2M | ||||||||
| Gritstone Oncology IncCOM · shares 0% · price +3.9% | 0.50% | $8.3M | +$311,000 | ||||||||
| Mohawk Group Hldgs IncCOM · shares 0% · price −24.7% | 0.38% | $6.2M | −$2.0M | ||||||||
| Ideaya Biosciences IncCOM · shares 0% · price −16.7% | 0.34% | $5.6M | −$1.1M | ||||||||
| Cloudera IncCOM · shares 0% · price +31.2% | 0.30% | $5.0M | +$1.2M | ||||||||
| Evelo Biosciences IncCOM · shares 0% · price −33.4% | 0.26% | $4.3M | −$2.2M | ||||||||
| Alector IncCOM · shares −11% · price +19.5% | 0.18% | $3.0M | +$493,647 | ||||||||
| Dropbox IncCL A · shares 0% · price −11.4% | 0.01% | $233,000 | −$30,000 | ||||||||
| Total · 24 positions | 100% | $1.65B | +$187.5M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q3 2019 to Q4 2019: 22 stocks held throughout, up $187.5M (+14.8%).
- Jd Com Inc+$95.1M+25%
- Forty Seven Inc+$34.0M+513%
- Lyft Inc+$28.0M+5%
- Magenta Therapeutics Inc+$16.4M+48%
- Dexcom Inc+$7.7M+47%
- Slack Technologies Inc.−$1.6M−5%
- Mohawk Group Hldgs Inc−$2.0M−25%
- Evelo Biosciences Inc−$2.2M−33%
- Cloudflare−$2.5M−8%
- Uber−$2.8M−2%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |